News
Events
Overview
Rationale for Immunodrugs™
Strategy
Board & Management
Industry Collaborations
Letter of the CEO
History
Overview
Immunodrug™ Platform
Immunodrug™ Manufacturing
Scientific Collaborations
Scientific Publications
Pipeline
Clinical Trials
Disease Areas
Overview
Board & Management
Share Information
Bond Information
Analyst Coverage
Financial Calendar
Financial Reports
Corporate Governance
Stay Informed
Contact
Overview
Press Release Archive
Downloads
Picture Gallery
Contact
Preventing Chronic Diseases
– a Vital Investment
Cytos
Press Releases
 
Cytos
Facts & Figures
 
Cytos Biotechnology AG
Wagistrasse 25
Postfach
8952 Schlieren
Switzerland
T +41 44 733 47 47
F +41 44 733 47 40
e-mail contact

Novel vaccines for chronic disease treatment and prevention

Cytos Biotechnology is dedicated to the discovery, development and commercialization
of a novel class of medicines – called Immunodrugs™. Immunodrugs™ are therapeutic
vaccines intended for use in the treatment and prevention of common chronic diseases
which afflict millions of people worldwide.

Important legal information: please read the disclaimer before proceeding.
News

 

2010, July 22:
Cytos' second quarter report.


2010, July 15:
A*STAR & Cytos Biotechnology establish influenza vaccine collaboration.


2010, July 5:
Matter Group AG holds 3.4155% of share capital.